acute sinusitis

Telithromycin (HMR3647) is a ketolide antibiotic to treat community acquired pneumonia of mild to moderate severity. Antibacterial Telithromycin prevents bacteria from growing, by interfering with their protein synthesis. Telithromycin binds to the subunit 50S of the bacterial ribosome, and blocks the progression of the growing polypeptide chain. Telithromycin has over 10 times higher affinity to the subunit 50S than erythromycin. In addition, telithromycin strongly bind simultaneously to two domains of 23S RNA of the 50 S ribosomal subunit, where older macrolides bind strongly only to one domain and weakly to the second domain. Telithromycin can also inhibit the formation of ribosomal subunits 50S and 30S.

Cefpodoxime proxetil-d3 is a deuterated compound of Cefpodoxime proxetil. Cefpodoxime proxetil has a CAS number of 87239-81-4. Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.

Fenspiride hydrochloride (Decaspiride) , an oxazolidinone spiro compound, is a drug used in the therapy of certain respiratory diseases. It is approved for use in Russia for the therapy of chronic and acute inflammatory diseases of ENT organs and the respiratory tract (like sinusitis, tracheobronchitis, otitis, laryngitis, and rhinopharyngitis), and for maintenance therapy of asthma.

Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is a

Decarboxy Moxifloxacin is a decarboxylated compound of moxifloxacin. Moxifloxacin is an oral active 8-methoxyquinolone antibiotic used in acute bacterial sinusitis, chronic bronchitis, acute bacterial deterioration, and community-acquired pneumonia.

IDR 1002, an innate defense regulator peptide, effectively diminishes bacterial load and mitigates inflammatory responses in murine models of sinusitis and acute bacterial lung infections. It suppresses LPS-induced activation of NF-κB and COX-2 while promoting the phosphorylation and activation of p38, ERK1/2, MSK1, and CREB.

Moxifloxacin hydrochloride (BAY12-8039 HCl) is a fourth generation fluoroquinolone with expanded activity against gram-positive bacteria as well as atypical pathogens. Moxifloxacin has been linked to mild ALT elevations during therapy and to rare instances of idiosyncratic acute liver injury with symptoms and jaundice.